Archives: Agenda

GlobalData’s clinical trials data indicates that new trials initiated in H1 2025 has increased significantly over previous years. In addition to surprising Wall Street, this has shaken up the biopharma competitive landscape and created major opportunities for CROs, CDMOs, Pharma Tech, and consultancies. Behind the headlines, clinical trial reporting lags, shifting start dates, and withdrawals make it easy to miss where the real growth is happening.

This session breaks down what drove the surge, where the next wave is coming from, and how early signals can give you the edge on predicting future market shifts. Whether you run trials, manufacture at scale, or advise life sciences companies, this is about being prepared, before your competitors are.

With drinks and refreshments, interactive roundtable sessions offer a unique opportunity to come together with your peers to share best practice and develop solutions to critical challenges facing the industry as a whole. Each discussion will run twice and be led by a table moderator and will focus on a different challenge within clinical trials. Roundtables are an exciting, interactive way to build your personal network and learn from the experience and expertise of others.

• Working closely with FSP vendors: how much oversight do you need?
• Benefits and challenges of moving to an FSP outsourcing model
• Comparing vendor management strategies between pharma and biotechs: do you need a different approach?
• Why is FSP becoming a popular outsourcing model: what benefits can this offer sponsors?

Moderator: Amanda Murphy, Senior Director, Data Intelligence & Solutions, GlobalData

• Determining team bandwidth
• Assessing clinical trial needs
• Shopping for the right CRO(s)
• Lessons learned from outsourcing

• Setting up for success with large CROs in terms of contract structures, financial terms and governance from a small biotech perspective
• Implementing a gold standard strategic partnership to avoid common pitfalls and improve vendor selection
• Knowing when to outsource and detailing key activities to be performed for each vendor service to ensure proper oversight
• Factoring in necessary contracts and approvals for vendor selection in study timelines

Moderator: Robert Loll, SVP, Business Development & Strategic Planning, Praxis

• Predict high-performing sites and investigators to accelerate enrolment
• Forecast site activation timelines with greater accuracy
• Anticipate post-marketing commitments earlier in the process
• Enhance TMF compliance and quality through intelligent automation
• Accelerate and streamline site contracting for faster study start-up
• Drive operational efficiency and cost savings through robotic process automation

• Growing in a thoughtful manner to ensure FDA inspection readiness
• Allowing future studies to benefit from standards established and remained consistent right from the start
• Engaging in respectful partnerships and supporting a demand-driven basis, aligning with country-driven strategies and procedures

• When the demand for research sites is growing and supply is failing to keep up, what can be done for competing trials?
• Dealing with exorbitant startup fees imposed by sites, with no guarantee of patient enrolment
• Elevating site support with comprehensive budgets and accelerated site payments
• Enabling appropriate technology for sponsors to easy access patients’ EMR
• Working to identify “hidden” costs and trial efforts that sites may not anticipate before negotiations
• Overcoming outdated paradigms that threaten site-sponsor relationships
• Carving out a niche to set you apart from the crowd to enable access to sites and patient populations